Results 61 to 70 of about 1,341 (183)
Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting? [PDF]
, 2022 The study of the pharmacological properties of an antifungal agent integrates the drug pharmacokinetics, the fungal growth inhibition, the fungicidal effect and the postantifungal activity, laying the basis to guide optimal dosing regimen selection.
Eraso, Elena +5 more
core +2 more sources
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus [PDF]
Antimicrobial Agents and Chemotherapy, 2019 We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus .
Nathan P. Wiederhold +6 more
openaire +2 more sources
Echinocandins – structure, mechanism of action and use in antifungal therapy
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022 With increasing number of immunocompromised patients as well as drug resistance in fungi, the risk of fatal fungal infections in humans increases as well.
Mateusz Szymański +4 more
doaj +1 more source
Antifungal resistance, combinations and pipeline: oh my!
Drugs in Context, 2023 Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover +4 more
doaj +1 more source
Development of the Invasive Candidiasis Discharge [I Can Discharge] Model: A Mixed Methods Analysis [PDF]
, 2022 Patients with invasive candidiasis (IC) have complex medical and infectious disease problems that often require continued care after discharge. This study aimed to assess echinocandin use at hospital discharge and develop a transition of care (TOC) model
Almutairi, Masaad Saeed +9 more
core +3 more sources
Journal of Fungi, 2023 The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti +3 more
doaj +1 more source
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Journal of Fungi, 2022 The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
2389. Effect of Rezafungin on QT Interval in Healthy Subjects [PDF]
Open Forum Infectious Diseases, 2018 BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation.
Flanagan, Shawn +5 more
openaire +1 more source
982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin [PDF]
Open Forum Infectious Diseases, 2021 Abstract Background Rezafungin (RZF) is a novel echinocandin antifungal being developed for treatment of candidemia and invasive candidiasis, and for prevention of invasive fungal diseases among immunosuppressed patients.
Huguet, Jade +6 more
openaire +1 more source
Journal of Fungi, 2022 The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi +12 more
doaj +1 more source